NEW YORK (GenomeWeb News) – MDxHealth today said that it has licensed to Takara Bio non-exclusive worldwide rights to its methylation-specific PCR technology.
Japan-based Takara has licensed the technology for the scientific research market. In exchange, MDxHealth will receive an upfront fee and royalties on sales of products incorporating the MSP technology. The firms did not disclose additional terms.
MDxHealth is based in Liege, Belgium, and formerly operated under the name OncoMethylome Sciences. The firm plans to leverage its methylation platform to develop DNA-based assays, which will then be offered through CLIA-certified laboratories in the US.